https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=CTI_BIOPHARMA 2026-05-06T22:31:47Z Istoricul versiunilor pentru această pagină din wiki MediaWiki 1.39.2 https://wiki.tradeville.ro/index.php?title=CTI_BIOPHARMA&diff=448021&oldid=prev 2024-09-30T04:54:57Z

<p>The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ro"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Versiunea anterioară</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Versiunea de la data 30 septembrie 2024 07:54</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Linia 2:</td> <td colspan="2" class="diff-lineno">Linia 2:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>CTI BioPharma Corp. (www.ctibiopharma.com) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>CTI BioPharma Corp. (www.ctibiopharma.com) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in <ins style="font-weight: bold; text-decoration: none;">[[SELECT|</ins>select<ins style="font-weight: bold; text-decoration: none;">]] </ins>countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td></tr> <!-- diff cache key tradeville_wiki:diff::1.12:old-414811:rev-448021 --> </table>

127.0.0.1 https://wiki.tradeville.ro/index.php?title=CTI_BIOPHARMA&diff=414811&oldid=prev 2024-09-18T17:47:58Z

<p>Pagină nouă: Pagina dedicata companiei CTI BIOPHARMA listata cu simbolul US.CTIC ==Descriere companie== CTI BioPharma Corp. (www.ctibiopharma.com) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressi...</p> <p><b>Pagină nouă</b></p><div>Pagina dedicata companiei CTI BIOPHARMA listata cu simbolul US.CTIC<br /> <br /> ==Descriere companie==<br /> CTI BioPharma Corp. (www.ctibiopharma.com) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.<br /> <br /> ==Grafic actiuni companie==<br /> &lt;iframe key=&quot;tradeville&quot; path=&quot;graficSimbol/US.CTIC&quot; /&gt;<br /> <br /> ==Ultimele stiri despre CTI BIOPHARMA (US.CTIC)==<br /> &lt;dynamicpagelist&gt;<br /> category=US.CTIC<br /> count=10<br /> order=descending<br /> addfirstcategorydate=false<br /> &lt;/dynamicpagelist&gt;<br /> <br /> [[Categorie:US.CTIC]][[Categorie:Stiri despre companii]]</div>

Admin